ImmunoPrecise Antibodies (IPA) Pioneers AI-Designed GLP-1 Therapies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/25/2026
- S&P 500 ends marginally lower as investors focus on US-Iran war
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oil gains on little sign of progress in US-Iran talks
- S&P 500 history shows strong gains across Fed hiking cycles: BCA
- JPMorgan upgrades CoreWeave on stronger compute pricing
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- US and Iran discuss phased deal to reopen Hormuz and end US blockade, sources say
IPA (ImmunoPrecise Antibodies) Pioneers AI-Designed GLP-1 Therapies: A Potential New Chapter in Diabetes Treatment
January 22, 2025 7:02 AM ESTAUSTIN, Texas--(BUSINESS WIRE)-- ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) has developed a new class of GLP-1 therapies entirely through artificial intelligence, designed to enhance efficacy, safety, therapy longevity, and patient satisfaction in diabetes treatment. These AI-designed therapeutics aim to improve upon current GLP-1 therapies, which are widely used for managing type 2 diabetes and obesity. Created using the Company's proprietary LENSai platform, an AI-driven system that analyzes evolutionary patterns in biological data, these novel AI-generated sequences have been optimized to maximize therapeutic performance while improving the patient experience. Enhancements are aimed at increased patentability,... More
